Ann: CE Mark Granted for ColoSTAT, page-30

smokeyd - also I am fairly sure that Sonic has either "a" contract or "the" contract for the logistics and testing of the FIT test in Australia. They may be on a good wicket with the FIT contracts so they may see ColoSTAT as a threat rather than as an opportunity.

I have to say I find the market response so far to the CE Mark news to be surprisingly tepid. I understand that the CE Mark approval goes to safety and fitness for purpose rather than how ColoSTAT actually performs. Notwithstanding that, it surely is a huge milestone for the product and the company.

I also have trouble reconciling the predicted income stream for FY23 and FY24 assumed by say, MST Assess in the report they put out the other week (which is on the Rhythm website) ($5m in FY23 and $17m in FY24) and the numbers being used by Rhythm eg an addressable market in Europe alone of US$12b. Even assuming that only European countries take up ColoSTAT that suggests that ColoSTAT will only have tapped into about 0.1% of the market in the next 30 months or so. I am clearly missing something.